We speculate that both the reduction of tumor infiltrating regulatory CD4 T cells and costimulation of effector T cells by aGITR contributed the enhancement of active immunization with aCD122 therapy; additional studies will be required to address this. This evidence concerns the gene CD4 and neoplasm.